Rheincell Therapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
17
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$30.7M
Rheincell Therapeutics General Information
Description
Provider of cell therapeutics created for the treatment of age-related macular degeneration. The company's cell therapeutics use cord blood as a stem cell source and the most advanced molecular technologies for reprogramming and the most sensitive molecular genetic methods available, enabling pharmaceutical companies to reduce cost and time required by them in introducing medicines.
Contact Information
Website
www.rheincell.deCorporate Office
- Berghausener Strasse 98
- 40764 Langenfeld
- Germany
Corporate Office
- Berghausener Strasse 98
- 40764 Langenfeld
- Germany
Rheincell Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 04-Aug-2021 | $30.7M | Completed | Generating Revenue | ||
| 1. Angel (individual) | 01-Aug-2017 | Completed | Generating Revenue |
Rheincell Therapeutics Comparisons
Industry
Financing
Details
Rheincell Therapeutics Competitors (53)
One of Rheincell Therapeutics’s 53 competitors is bit.bio, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| bit.bio | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Aviva Systems Biology | Formerly VC-backed | San Diego, CA | ||||
| U.S. Stem Cell | Formerly VC-backed | Sunrise, FL | ||||
| Novus Biologicals | Formerly PE-Backed | Centennial, CO | ||||
| Regenerative Patch Technologies | Venture Capital-Backed | Portola Valley, CA |
Rheincell Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Rheincell Therapeutics Patents
Rheincell Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3153576-A1 | Improved expansion of eukaryotic cells | Inactive | 09-Oct-2015 | ||
| DE-102015107285-A1 | Isolated increased hepatocyte-like human cells | Inactive | 11-May-2015 |
Rheincell Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Rheincell Therapeutics FAQs
-
When was Rheincell Therapeutics founded?
Rheincell Therapeutics was founded in 2015.
-
Where is Rheincell Therapeutics headquartered?
Rheincell Therapeutics is headquartered in Langenfeld, Germany.
-
What is the size of Rheincell Therapeutics?
Rheincell Therapeutics has 17 total employees.
-
What industry is Rheincell Therapeutics in?
Rheincell Therapeutics’s primary industry is Biotechnology.
-
Is Rheincell Therapeutics a private or public company?
Rheincell Therapeutics is a Private company.
-
What is the current valuation of Rheincell Therapeutics?
The current valuation of Rheincell Therapeutics is .
-
What is Rheincell Therapeutics’s current revenue?
The current revenue for Rheincell Therapeutics is .
-
Who are Rheincell Therapeutics’s competitors?
bit.bio, Aviva Systems Biology, U.S. Stem Cell, Novus Biologicals, and Regenerative Patch Technologies are some of the 53 competitors of Rheincell Therapeutics.
-
When was Rheincell Therapeutics acquired?
Rheincell Therapeutics was acquired on 04-Aug-2021.
-
Who acquired Rheincell Therapeutics?
Rheincell Therapeutics was acquired by Catalent.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
